policresulen
Negatol (Policresulen) is a topical hemostatic and antiseptic indicated for common anal disorders, such as hemorrhoids, and for gynecological infections. Policresulen has hemostatic activity by causing coagulation of blood proteins and promoting the contraction of the muscular fibers of the blood vessels of small caliber. Policresulen promotes selective chemical debridement: being an anion, it has the ability to interact only with the phospholipid molecules of the plasma membranes of to devitalized cells, which have lost its original electric charge. This contact provides the denaturation of cellular proteins, facilitating their removal. Its acidity, together with coagulating properties, give policresulen antimicrobial activity against staphylococcus spp., streptococcus spp. and Candida albicans. Policresulen is often used for gynecological infections. It is also used to treat canker sore in some countries. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2016 (NCT02890277)
Timeline
No events for the selected filters.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPolicresulen ↗
- NCATS6I19M5GB0G ↗
- ChEMBLCHEMBL2106937 ↗
Also known as
- albocresil
- albothyl
- formaldehyde - meta-cresolsulfonic acid
- formaldehyde, meta-cresolsulfonic acid drug combination
- lotagen
- negatan
- negatol
- novugen
- policresulen
- policresulen
- policresulen
- policresulen
- policresulen
- policresulen
- vagothyl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02890277 | N/A | Jan 1, 2016 | People's Liberation Army of China |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2016 |